



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/00, 45/00, 45/05, A01H 63/00	A1	(11) International Publication Number: WO 98/14206 (43) International Publication Date: 9 April 1998 (09.04.98)
(21) International Application Number: PCT/US97/15741 (22) International Filing Date: 2 October 1997 (02.10.97) (30) Priority Data: 60/027,002 ✓ 4 October 1996 (04.10.96) ✓ US (71) Applicant: THOMAS JEFFERSON UNIVERSITY [US/US]; 11th and Walnut Streets, Philadelphia, PA 19107 (US). (72) Inventors: BERD, David; 125 Heathcock Lane, Wyncote, PA 19095 (US); PARMIANI, Giorgio; Istituto Nazionale per lo Studio e la Cura Tumori, Divisione di Oncologia Sperimentale, Via Venezia, I-20133 Milano (IT); ANICHINI, Andrea; Via Cinquantenario, I-17-24044 Dalmine (IT); SENSI, Maria Luisa; Piazza Donegani, I-6-20133 Milano (IT). (74) Agents: JOHNSON, Philip, S. et al.; Woodcock Washburn Kurtz Mackiewicz & Norris LLP, 46th floor, One Liberty Place, Philadelphia, PA 19103 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.
(54) Title: T CELLS MEDIATING AN IMMUNE RESPONSE AND METHODS OF USE (57) Abstract The present invention is directed to T cells, compositions, and methods of obtaining and using the same, including and not limited to methods of treating cancer. The methods of the present invention include <i>inter alia</i>: a method of generating T cells capable of infiltrating a tumor of a human and participating in an immune response against the tumor; and a method of treating cancer comprising administering to a human afflicted with a tumor a therapeutically effective amount of T cells that mediate tumor regression, the T cells having been either isolated from the tumor of the human after immunization of the human with a composition comprising hapten-modified tumor cells and/or expanded <i>in vitro</i> from T cells thus isolated.		